ICU Medical Reports Q3 Revenue of $537 Million and Net Loss of $3.4 Million

Reuters11-07

ICU Medical Reports Q3 Revenue of $537 Million and Net Loss of $3.4 Million

ICU Medical Inc. reported third quarter 2025 revenue of $537.0 million, down from $589.1 million in the same period of 2024. GAAP gross profit was $200.9 million, compared to $204.9 million the previous year, with a GAAP gross margin of 37% versus 35% in 2024. The company reported a GAAP net loss of $3.4 million, or $0.14 per diluted share, compared to a net loss of $33.0 million, or $1.35 per diluted share, in the third quarter of 2024. Adjusted diluted earnings per share were $2.03, up from $1.59 last year, and adjusted EBITDA was $105.9 million, compared to $94.8 million in the prior year. By product line for the quarter, Consumables revenue was $285.1 million, up $20.2 million; Infusion Systems revenue was $173.9 million, up $14.1 million; and Vital Care revenue was $78.0 million, down $86.5 million from the previous year. The company updated its full year 2025 guidance, raising its expected adjusted EBITDA to between $395 million and $405 million, and adjusted diluted earnings per share to a range of $7.35 to $7.65.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ICU Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570679-en) on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581010966?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581010966","market":"fut","top_or_hot":-1,"title":"ICU Medical Reports Q3 Revenue of $537 Million and Net Loss of $3.4 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ICU Medical Reports Q3 Revenue of $537 Million and Net Loss of $3.4 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ICU Medical Inc. reported third quarter 2025 revenue of $537.0 million, down from $589.1 million in the same period of 2024. GAAP gross profit was $200.9 million, compared to $204.9 million the previous year, with a GAAP gross margin of 37% versus 35% in 2024. The company reported a GAAP net loss of $3.4 million, or $0.14 per diluted share, compared to a net loss of $33.0 million, or $1.35 per diluted share, in the third quarter of 2024. Adjusted diluted earnings per share were $2.03, up from $1.59 last year, and adjusted EBITDA was $105.9 million, compared to $94.8 million in the prior year. By product line for the quarter, Consumables revenue was $285.1 million, up $20.2 million; Infusion Systems revenue was $173.9 million, up $14.1 million; and Vital Care revenue was $78.0 million, down $86.5 million from the previous year. The company updated its full year 2025 guidance, raising its expected adjusted EBITDA to between $395 million and $405 million, and adjusted diluted earnings per share to a range of $7.35 to $7.65.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ICU Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570679-en) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ICU Medical Reports Q3 Revenue of $537 Million and Net Loss of $3.4 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nICU Medical Reports Q3 Revenue of $537 Million and Net Loss of $3.4 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ICU Medical Reports Q3 Revenue of $537 Million and Net Loss of $3.4 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ICU Medical Inc. reported third quarter 2025 revenue of $537.0 million, down from $589.1 million in the same period of 2024. GAAP gross profit was $200.9 million, compared to $204.9 million the previous year, with a GAAP gross margin of 37% versus 35% in 2024. The company reported a GAAP net loss of $3.4 million, or $0.14 per diluted share, compared to a net loss of $33.0 million, or $1.35 per diluted share, in the third quarter of 2024. Adjusted diluted earnings per share were $2.03, up from $1.59 last year, and adjusted EBITDA was $105.9 million, compared to $94.8 million in the prior year. By product line for the quarter, Consumables revenue was $285.1 million, up $20.2 million; Infusion Systems revenue was $173.9 million, up $14.1 million; and Vital Care revenue was $78.0 million, down $86.5 million from the previous year. The company updated its full year 2025 guidance, raising its expected adjusted EBITDA to between $395 million and $405 million, and adjusted diluted earnings per share to a range of $7.35 to $7.65.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ICU Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570679-en) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL9McDyF:1","article_id":"2581010966","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581010966","pubTimestamp":1762463321,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ICU Medical Inc. reported third quarter 2025 revenue of $537.0 million, down from $589.1 million in the same period of 2024. GAAP gross profit was $200.9 million, compared to $204.9 million the previous year, with a GAAP gross margin of 37% versus 35% in 2024. The company reported a GAAP net loss of $3.4 million, or $0.14 per diluted share, compared to a net loss of $33.0 million, or $1.35 per diluted share, in the third quarter of 2024. Adjusted diluted earnings per share were $2.03, up from $1.59 last year, and adjusted EBITDA was $105.9 million, compared to $94.8 million in the prior year. By product line for the quarter, Consumables revenue was $285.1 million, up $20.2 million; Infusion Systems revenue was $173.9 million, up $14.1 million; and Vital Care revenue was $78.0 million, down $86.5 million from the previous year. The company updated its full year 2025 guidance, raising its expected adjusted EBITDA to between $395 million and $405 million, and adjusted diluted earnings per","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4588":"碎股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU0240878834.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" (USD) INC AV","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","SG9999015978.USD":"利安颠覆性创新基金A","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","BK4585":"ETF&股票定投概念","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4198":"医疗保健用品","LU0240877869.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","ICUI":"ICU医疗","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC"},"translate_title":"ICU Medical报告第三季度营收5.37亿美元，净亏损340万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICUI":0.9,"NDAQ":0.9},"content_text":"ICU Medical Reports Q3 Revenue of $537 Million and Net Loss of $3.4 Million\n    \n\n        ICU Medical Inc. reported third quarter 2025 revenue of $537.0 million, down from $589.1 million in the same period of 2024. GAAP gross profit was $200.9 million, compared to $204.9 million the previous year, with a GAAP gross margin of 37% versus 35% in 2024. The company reported a GAAP net loss of $3.4 million, or $0.14 per diluted share, compared to a net loss of $33.0 million, or $1.35 per diluted share, in the third quarter of 2024. Adjusted diluted earnings per share were $2.03, up from $1.59 last year, and adjusted EBITDA was $105.9 million, compared to $94.8 million in the prior year. By product line for the quarter, Consumables revenue was $285.1 million, up $20.2 million; Infusion Systems revenue was $173.9 million, up $14.1 million; and Vital Care revenue was $78.0 million, down $86.5 million from the previous year. The company updated its full year 2025 guidance, raising its expected adjusted EBITDA to between $395 million and $405 million, and adjusted diluted earnings per share to a range of $7.35 to $7.65.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ICU Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570679-en) on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581010966","isCrawlerRequest":true}